386 related articles for article (PubMed ID: 29512074)
1. Amyloid PET Imaging: Standardization and Integration with Other Alzheimer's Disease Biomarkers.
Morbelli S; Bauckneht M
Methods Mol Biol; 2018; 1750():203-212. PubMed ID: 29512074
[TBL] [Abstract][Full Text] [Related]
2. Amyloid PET Imaging: Standard Procedures and Semiquantification.
D'Amico F; Sofia L; Bauckneht M; Morbelli S
Methods Mol Biol; 2024; 2785():165-175. PubMed ID: 38427194
[TBL] [Abstract][Full Text] [Related]
3. Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection.
Ikonomovic MD; Buckley CJ; Heurling K; Sherwin P; Jones PA; Zanette M; Mathis CA; Klunk WE; Chakrabarty A; Ironside J; Ismail A; Smith C; Thal DR; Beach TG; Farrar G; Smith AP
Acta Neuropathol Commun; 2016 Dec; 4(1):130. PubMed ID: 27955679
[TBL] [Abstract][Full Text] [Related]
4. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease.
Ikonomovic MD; Klunk WE; Abrahamson EE; Mathis CA; Price JC; Tsopelas ND; Lopresti BJ; Ziolko S; Bi W; Paljug WR; Debnath ML; Hope CE; Isanski BA; Hamilton RL; DeKosky ST
Brain; 2008 Jun; 131(Pt 6):1630-45. PubMed ID: 18339640
[TBL] [Abstract][Full Text] [Related]
5. Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid-β plaques in Alzheimer's disease.
Ikonomovic MD; Buckley CJ; Abrahamson EE; Kofler JK; Mathis CA; Klunk WE; Farrar G
Acta Neuropathol; 2020 Oct; 140(4):463-476. PubMed ID: 32772265
[TBL] [Abstract][Full Text] [Related]
6. Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease.
Kadir A; Marutle A; Gonzalez D; Schöll M; Almkvist O; Mousavi M; Mustafiz T; Darreh-Shori T; Nennesmo I; Nordberg A
Brain; 2011 Jan; 134(Pt 1):301-17. PubMed ID: 21149866
[TBL] [Abstract][Full Text] [Related]
7. Positron emission tomography radiopharmaceuticals for imaging brain Beta-amyloid.
Vallabhajosula S
Semin Nucl Med; 2011 Jul; 41(4):283-99. PubMed ID: 21624562
[TBL] [Abstract][Full Text] [Related]
8. Biopathological Significance of Early-Phase Amyloid Imaging in the Spectrum of Alzheimer's Disease.
Bunai T; Kakimoto A; Yoshikawa E; Terada T; Ouchi Y
J Alzheimers Dis; 2019; 69(2):529-538. PubMed ID: 31104023
[TBL] [Abstract][Full Text] [Related]
9. Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG.
Shin J; Lee SY; Kim SJ; Kim SH; Cho SJ; Kim YB
Neuroimage; 2010 Aug; 52(2):488-96. PubMed ID: 20385246
[TBL] [Abstract][Full Text] [Related]
10. [(18)F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid β detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies.
Rinne JO; Wong DF; Wolk DA; Leinonen V; Arnold SE; Buckley C; Smith A; McLain R; Sherwin PF; Farrar G; Kailajärvi M; Grachev ID
Acta Neuropathol; 2012 Dec; 124(6):833-45. PubMed ID: 23053137
[TBL] [Abstract][Full Text] [Related]
11. Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer's subjects.
Mountz JM; Laymon CM; Cohen AD; Zhang Z; Price JC; Boudhar S; McDade E; Aizenstein HJ; Klunk WE; Mathis CA
Neuroimage Clin; 2015; 9():592-8. PubMed ID: 26640770
[TBL] [Abstract][Full Text] [Related]
12. Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography.
Wolk DA; Zhang Z; Boudhar S; Clark CM; Pontecorvo MJ; Arnold SE
J Neurol Neurosurg Psychiatry; 2012 Sep; 83(9):923-6. PubMed ID: 22791901
[TBL] [Abstract][Full Text] [Related]
13. Biological characters of [18F]O-FEt-PIB in a rat model of Alzheimer's disease using micro-PET imaging.
Zheng MQ; Yin DZ; Zhang L; Lei B; Cheng DF; Cai HC; Han YJ; Wu MX; Zhang H; Wang J
Acta Pharmacol Sin; 2008 May; 29(5):548-54. PubMed ID: 18430362
[TBL] [Abstract][Full Text] [Related]
14. Preclinical Comparison of the Amyloid-β Radioligands [(11)C]Pittsburgh compound B and [(18)F]florbetaben in Aged APPPS1-21 and BRI1-42 Mouse Models of Cerebral Amyloidosis.
Waldron AM; Verhaeghe J; wyffels L; Schmidt M; Langlois X; Van Der Linden A; Stroobants S; Staelens S
Mol Imaging Biol; 2015 Oct; 17(5):688-96. PubMed ID: 25701131
[TBL] [Abstract][Full Text] [Related]
15. In vitro Characterization of the Regional Binding Distribution of Amyloid PET Tracer Florbetaben and the Glia Tracers Deprenyl and PK11195 in Autopsy Alzheimer's Brain Tissue.
Ni R; Röjdner J; Voytenko L; Dyrks T; Thiele A; Marutle A; Nordberg A
J Alzheimers Dis; 2021; 80(4):1723-1737. PubMed ID: 33749648
[TBL] [Abstract][Full Text] [Related]
16. Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer's disease and healthy controls.
Barthel H; Luthardt J; Becker G; Patt M; Hammerstein E; Hartwig K; Eggers B; Sattler B; Schildan A; Hesse S; Meyer PM; Wolf H; Zimmermann T; Reischl J; Rohde B; Gertz HJ; Reininger C; Sabri O
Eur J Nucl Med Mol Imaging; 2011 Sep; 38(9):1702-14. PubMed ID: 21547601
[TBL] [Abstract][Full Text] [Related]
17. Imaging β-amyloid using [(18)F]flutemetamol positron emission tomography: from dosimetry to clinical diagnosis.
Heurling K; Leuzy A; Zimmer ER; Lubberink M; Nordberg A
Eur J Nucl Med Mol Imaging; 2016 Feb; 43(2):362-373. PubMed ID: 26440450
[TBL] [Abstract][Full Text] [Related]
18. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study.
Sabri O; Sabbagh MN; Seibyl J; Barthel H; Akatsu H; Ouchi Y; Senda K; Murayama S; Ishii K; Takao M; Beach TG; Rowe CC; Leverenz JB; Ghetti B; Ironside JW; Catafau AM; Stephens AW; Mueller A; Koglin N; Hoffmann A; Roth K; Reininger C; Schulz-Schaeffer WJ;
Alzheimers Dement; 2015 Aug; 11(8):964-74. PubMed ID: 25824567
[TBL] [Abstract][Full Text] [Related]
19. Dynamic relationships between age, amyloid-β deposition, and glucose metabolism link to the regional vulnerability to Alzheimer's disease.
Oh H; Madison C; Baker S; Rabinovici G; Jagust W
Brain; 2016 Aug; 139(Pt 8):2275-89. PubMed ID: 27190008
[TBL] [Abstract][Full Text] [Related]
20. Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET.
Okamura N; Furumoto S; Fodero-Tavoletti MT; Mulligan RS; Harada R; Yates P; Pejoska S; Kudo Y; Masters CL; Yanai K; Rowe CC; Villemagne VL
Brain; 2014 Jun; 137(Pt 6):1762-71. PubMed ID: 24681664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
